Prof. Dr. Johannes von Kempis
Rheumatologie · Dept. I
Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland
von Kempis J, Duetsch S, Reuschling N, Villiger R, Villiger P, Vallelian F, Schaer D, Mueller R. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland. Swiss Med Wkly 2019; 149:w20022.
10.03.2019Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland
10.03.2019Swiss Med Wkly 2019; 149:w20022
von Kempis Johannes, Duetsch Sabine, Reuschling Nicola, Villiger Rahel, Villiger Peter M, Vallelian Florence, Schaer Dominik J, Mueller Ruediger B
51-year-old man with with acute coronary syndrome and bipulmonary infiltrates
von Kempis J, Deutsche S, Reschling N, Villiger R, Villiger P, Vallelian F, Scher D, Mueller R. 51-year-old man with with acute coronary syndrome and bipulmonary infiltrates. Swiss Medical Weekly 2019; 2019;149:w20022
10.03.201951-year-old man with with acute coronary syndrome and bipulmonary infiltrates
10.03.2019Swiss Medical Weekly 2019; 2019;149:w20022
von Kempis Johannes, Deutsche Sabine, Reschling Nicola, Villiger Rahel, Villiger Peter M, Vallelian Florence, Scher Dominik, Mueller Ruediger B
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
Mueller R, Spaeth M, von Restorff C, Ackermann C, Schulze-Koops H, von Kempis J. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. J Clin Med 2019; 8
03.03.2019Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
03.03.2019J Clin Med 2019; 8
Mueller Ruediger B, Spaeth Michael, von Restorff Cord, Ackermann Christoph, Schulze-Koops Hendrik, von Kempis Johannes
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
Müller R, Spaeth M, von Restorff C, Ackermann C, Schulze-Koops H, von Kempis J. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. Journal of Clinical Medicine 2019; 8:302.
03.03.2019Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
03.03.2019Journal of Clinical Medicine 2019; 8:302
Müller Rüdiger B, Spaeth Michael, von Restorff Cord, Ackermann Christoph, Schulze-Koops Hendrik, von Kempis Johannes
Important differential diagnosis in acute tenosynovitis
Pirker I, Rein P, von Kempis J. Important differential diagnosis in acute tenosynovitis. BMJ Case Rep 2019; 12
10.01.2019Important differential diagnosis in acute tenosynovitis
10.01.2019BMJ Case Rep 2019; 12
Pirker Ian Franz Josef, Rein Philipp, von Kempis Johannes
The Value of an Automated Ultrasound System in the Detection of Synovitis
Mueller R, Grunke M, Wendler J, Schuch F, Hofmann-Preiss K, Boettger I, Jakobs R, Schulze-Koops H, von Kempis J. The Value of an Automated Ultrasound System in the Detection of Synovitis. Ultrasound Int Open 2018; 4:E61-E68.
11.07.2018The Value of an Automated Ultrasound System in the Detection of Synovitis
11.07.2018Ultrasound Int Open 2018; 4:E61-E68
Mueller Ruediger, Grunke Mathias, Wendler Jörg, Schuch Florian, Hofmann-Preiss Karina, Boettger Ina, Jakobs Rüdiger, Schulze-Koops Hendrik, von Kempis Johannes
Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort
Mueller R, Kaegi T, Haile S, Schulze-Koops H, Schiff M, von Kempis J. Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort. RMD Open 2018; 4:e000673.
06.06.2018Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort
06.06.2018RMD Open 2018; 4:e000673
Mueller Ruediger B, Kaegi Toni, Haile Sarah R, Schulze-Koops Hendrik, Schiff Michael, von Kempis Johannes
Improvement of primary biliary cholangitis (PBC) under treatment with sulfasalazine and abatacept
Popp F, Semela D, von Kempis J, Mueller R. Improvement of primary biliary cholangitis (PBC) under treatment with sulfasalazine and abatacept. BMJ Case Rep 2018; 2018
12.05.2018Improvement of primary biliary cholangitis (PBC) under treatment with sulfasalazine and abatacept
12.05.2018BMJ Case Rep 2018; 2018
Popp Florian, Semela David, von Kempis Johannes, Mueller Ruediger B
Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort
Heinimann K, von Kempis J, Sauter R, Schiff M, Sokka-Isler T, Schulze-Koops H, Müller R. Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort. J Clin Med 2018; 7
13.03.2018Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort
13.03.2018J Clin Med 2018; 7
Heinimann Katja, von Kempis Johannes, Sauter Rafael, Schiff Michael, Sokka-Isler Tuulikki, Schulze-Koops Hendrik, Müller Rüdiger
[A Rare Differential Diagnosis of Chronic Cough]
Dicker M, Schneider T, von Kempis J, Diethelm M. [A Rare Differential Diagnosis of Chronic Cough]. Dtsch Med Wochenschr 2017; 142:1751-1755.
16.11.2017[A Rare Differential Diagnosis of Chronic Cough]
16.11.2017Dtsch Med Wochenschr 2017; 142:1751-1755
Dicker Michael, Schneider Tino, von Kempis Johannes, Diethelm Markus
Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
Müller R, Graninger W, Sidiropoulos P, Goger C, von Kempis J. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. Clin Rheumatol 2017; 36:2187-2192.
03.08.2017Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
03.08.2017Clin Rheumatol 2017; 36:2187-2192
Müller Rüdiger, Graninger Winfried, Sidiropoulos Paris, Goger Christoph, von Kempis Johannes
Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
Müller R, Graninger W, Sidiropoulos P, Goger C, von Kempis J. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. Clin Rheumatol 2017; 36:2187-2192.
03.08.2017Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
03.08.2017Clin Rheumatol 2017; 36:2187-2192
Müller Rüdiger, Graninger Winfried, Sidiropoulos Paris, Goger Christoph, von Kempis Johannes
Blue-Finger-Syndrome and Tofacitinib
Popp F, Benecke U, Fischer S, von Kempis J, Koeger P, Müller R. Blue-Finger-Syndrome and Tofacitinib - Case Report. Clinical Image: Annals of Clinical Case Reports 2017; 2
18.07.2017Blue-Finger-Syndrome and Tofacitinib
18.07.2017Clinical Image: Annals of Clinical Case Reports 2017; 2
Popp Florian, Benecke U, Fischer S, von Kempis Johannes, Koeger P, Müller Rüdiger
Granuloma Annulare, Drug-Induced Lupus and
Popp F, Fischer S, Kempf W, von Kempis J, Welcker M, Müller R. Granuloma Annulare, Drug-Induced Lupus and - Case Report. Clinical Image: Annals of Clinical Case Reports 2017; 2
17.04.2017Granuloma Annulare, Drug-Induced Lupus and
17.04.2017Clinical Image: Annals of Clinical Case Reports 2017; 2
Popp Florian, Fischer S, Kempf W, von Kempis Johannes, Welcker M, Müller Rüdiger
Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)
Chaigne B, Ribi C, von Kempis J, Stoll T, Dayer E, Huynh-Do U, Trendelenburg M, Perneger T, Chizzolini C, Swiss Systemic Lupus Erythematosus Cohort Study Group. Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). BMC Immunol 2017; 18:17.
28.03.2017Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)
28.03.2017BMC Immunol 2017; 18:17
Chaigne Benjamin, Ribi Camillo, von Kempis Johannes, Stoll Thomas, Dayer Eric, Huynh-Do Uyen, Trendelenburg Marten, Perneger Thomas, Chizzolini Carlo, Swiss Systemic Lupus Erythematosus Cohort Study Group
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)
Müller R, von Kempis J, Spaeth M, Schiff M, Schulze-Koops H, Haile S, Finckh A, Kaegi T, Reshiti N. Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). Clin Rheumatol 2016; 36:59-66.
12.11.2016Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)
12.11.2016Clin Rheumatol 2016; 36:59-66
Müller Rüdiger, von Kempis Johannes, Spaeth Michael, Schiff Michael, Schulze-Koops Hendrik, Haile Sarah R, Finckh Axel, Kaegi Toni, Reshiti Nazim
Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
Müller R, Gengenbacher M, Richter S, Dudler J, Möller B, von Kempis J. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). Arthritis Res Ther 2016; 18:88.
14.04.2016Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
14.04.2016Arthritis Res Ther 2016; 18:88
Müller Rüdiger, Gengenbacher Michael, Richter Symi, Dudler Jean, Möller Burkhard, von Kempis Johannes
Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort
Müller R, von Kempis J, Haile S, Schiff M. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Semin Arthritis Rheum 2015; 45:28-34.
03.03.2015Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort
03.03.2015Semin Arthritis Rheum 2015; 45:28-34
Müller Rüdiger, von Kempis Johannes, Haile Sarah, Schiff Michael H
The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland
Ribi C, Chizzolini C, von Kempis J, Stoll T, Spertini F, Otto P, Koenig K, Lindner G, Leimgruber A, Hunziker T, Hauser T, Eisenberger U, Dayer E, Cohen C, Gayet-Ageron A, Trendelenburg M, Swiss Systemic Lupus Erythematosus Cohort Study Group. The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Med Wkly 2014; 144:w13990.
07.08.2014The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland
07.08.2014Swiss Med Wkly 2014; 144:w13990
Ribi Camillo, Chizzolini Carlo, von Kempis Johannes, Stoll Thomas, Spertini François, Otto Petra, Koenig Katrin, Lindner Gregor, Leimgruber Annette, Hunziker Thomas, Hauser Thomas, Eisenberger Ute, Dayer Eric, Cohen Clemens, Gayet-Ageron Angèle, Trendelenburg Marten, Swiss Systemic Lupus Erythematosus Cohort Study Group
The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis
Müller R, Schiff M, Kaegi T, Finckh A, Haile S, Schulze-Koops H, von Kempis J, Swiss Clinical Quality Management (SCQM) physicians. The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis. Clin Rheumatol 2014; 34:51-9.
15.07.2014The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis
15.07.2014Clin Rheumatol 2014; 34:51-9
Müller Rüdiger, Schiff M, Kaegi T, Finckh A, Haile Sarah, Schulze-Koops H, von Kempis Johannes, Swiss Clinical Quality Management (SCQM) physicians